CD274 and non-small cell lung carcinoma: Monoclonal antibodies blocking the interaction of PD-1 and PD-L1 activate an individual’s immune system to attack their cancer and have revolutionized the landscape of cancer treatment, showing clinical benefit in multiple cancers, including NSCLC.